Interferon regulatory factor (IRF)-4 is a member of the IRF transcription factor family, whose expression is primarily restricted to lymphoid and myeloid cells.
Introduction
Interferons (IFNs) are multi-functional cytokines that regulate the genes involved in viral infection defense, immune system activation, hematopoietic development and modulation of cell growth. IFNs derive their effects through the transcriptional activation of target genes, which are regulated through IFN regulatory factors (IRFs). In mammals, the members of the IRF family of transcription factors (IRF-1~IRF-9) bind to the IFN-stimulated response elements (ISREs) found in the promoter regions of IFN-stimulated genes (1) .
The expression of IRF-4 is restricted to the immune system, and is induced by diverse mitogenic stimuli, including T-cell receptor (TCR) cross-linking or treatment with phorbol-12-myristate-13-acetate (PMA)/Ionomycin (I) (2) (3) (4) . Mice deficient in the IRF-4 gene (IRF-4 -/-) exhibited profound defects in the functions of both B-and T-cells (5) . IRF-4 plays crucial roles in multiple steps of B-cell differentiation. For instance, IRF-4 activates the immunoglobulin light-chain genes by binding a specific DNA sequence in the 3' enhancer regions, in cooperation with the ETS-family transcription factor PU.1, and by repressing the key germinal center regulator, BCL6 (6, 7) . Recently, IRF-4 was reported to be the master regulator gene in multiple myeloma, a malignancy of plasma cells (7, 8) .
IRF-4 is also essential for several stages of T-cell and myeloid cell differentiation. We, as well as other groups, have found that, in the absence of IRF-4, not only the development of Th2 but also that of a cDC subset, CD8 -CD11b + , is severely impaired (9) (10) (11) (12) . The IRF-4 functions are regulated by several IRF-4-binding proteins. FK506-binding protein 52 (FKBP52) reportedly bound to IRF-4 in HTLV-1 (human T-cell leukemia virus type 1)-infected T-cells, and repressed the IRF-4 function by preventing the nuclear translocation 5 and the target DNA binding of IRF-4 (13) . The IRF-4-dependent IL-4 induction in the presence of PMA and Ionomycin was enhanced by NFATc2 (NFAT1), and provided an important molecular function in T-helper cell (Th) differentiation (9) . NFATc1 (NFAT2) also activated the human IL-2 and IL-4 promoters in cooperation with IRF-4 (14) . Recently, it was reported that the elevated expressions of a nuclear factor-kappaB (NF-B) family member, c-Rel, and IRF-4 are associated with the prognosis in adult T-cell leukemia/lymphoma (ATLL) patients (15) . To elucidate the mechanism, we isolated IRF-4-binding proteins from the HTLV-1-infected T-cells (HUT102), using the tandem affinity purification (TAP) method (16) . We identified c-Rel, as a novel IRF-4-associated protein in T-cells. We further examined whether IRF-4 activates the promoters of IL-2 (a T-cell growth factor) and IL-4 (an inducer of Th2 differentiation and growth) in cooperation with c-Rel in the stimulated T-cells. 6 
Materials and Methods

Cell culture and transfection
HUT102, an HTLV-1-infected human T-cell line, and EL-4, a murine thymoma cell line, were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), and transfected with the indicated plasmids by electroporation using a pipette-type electroporator, Microporator MP-100 (Digital Bio). HEK293T cells were grown in 10% FBS-supplemented DMEM, and transfected with the indicated plasmids using the FuGENE 6 transfection reagent (Roche).
Plasmid constructs
The full-length human IRF-4 cDNA (1-1356) (2) , and the PCR-amplified DNA fragments, and (404-1356), were inserted downstream of the FLAG tag in the pcDNA3 vector (Invitrogen).
The unique restriction enzyme, ApaI, was used to excise the N-terminal (1-1174) and C-terminal (1174-1860) regions from the full-length human c-Rel cDNA (1-1860) (17) . The fragments were inserted downstream of the HA tag in the pcDNA3 vector. The IL-4-Luc reporter plasmid was constructed by inserting the PCR-amplified promoter region (-250 ~ +15) of the human IL-4 gene into the pGL2-Basic vector (Promega). All constructs were confirmed by DNA sequencing.
Preparation of cell extracts
Cell lysates were prepared by vigorous vortexing in 400 l of lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP40), containing a protease inhibitor mix (Boehringer), 48 hour after transfection in a 6-well plate.
For the preparation of the nuclear extract, HUT102 cells (1×10 6 cells) were transfected with the indicated plasmids, and the nuclear proteins were extracted as described 7 previously (18).
Immunoprecipitation and immunoblot analyses
The cell lysates were incubated with anti-FLAG M1 antibody-conjugated agarose beads (Sigma) for 2h at 4°C. The nuclear extracts from HUT102 cells were incubated with 5g of goat polyclonal anti-IRF-4 antibody (Santa Cruz Biotechnology), rabbit polyclonal anti-c-Rel antibody (Santa Cruz Biotechnology) or the corresponding control IgG antibody (Sigma), and Protein A Sepharose4B Fast Flow beads, for 3h at 4°C. The immunocomplexes were extensively washed, and the co-precipitated proteins were eluted from the Sepharose beads by boiling in SDS sample buffer. Each sample was resolved by SDS-PAGE, transferred to a PVDF membrane, and incubated with the indicated antibodies.
Specific proteins were visualized with the appropriate HRP-conjugated antibodies and the ECL Plus detection system (Amersham Pharmacia Biotech).
Chromatin immunoprecipitation (ChIP)
The nuclear extracts from HUT102 cells were subjected to DNA-protein cross-linking with 1% formaldehyde for 5min. After extensive washing, the samples were suspended in 500 μl of 150 mM NaCl, 25 mM Tris, pH 7.5, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate, and were sonicated. After centrifugation at 14,000 rpm for 10 min at 4°C, the supernatants were precipitated with 25 μg anti-IRF-4 antibody, Freshly isolated CD4 + T-cells, from the spleens of C57BL/6 and IRF-4 -/littermates, were treated continuously with TNF- (5 ng/ml) for 6h. The cells were then collected by centrifugation and cultured at a density of 1×10 6 cells/ml in six-well plates precoated with anti-TCR mAb (H57-597, 10 g/ml). Cells were harvested at 4h for RNA analyses.
RNA isolation and reverse-transcription PCR
Total RNA was extracted from the CD4 + T-cells and the HUT102 cells transfected with the indicated plasmids, using Isogen (Nippon Gene, Japan). cDNA was generated from 1 g RNA, using reverse transcriptase. The PCR primers used for human IL-2 were 5'-TGTACAGCATGCAGCTCGC-3' and 5'-TGCTTCCGCTGTAGAGCTTG-3', those for mouse IL-2 were 5'-GAGTCAAATCCAGAAGATGCCGCAG -3' and 5'-TGATGGACCTACAGGAGCTCCTGAG-3', those for mouse IL-4 were 
Intraperitoneal injections and cell isolation
Complete and incomplete Freund's adjuvants (CFA/IFA) were purchased from Difco
Laboratories. An emulsion (100 l) of CFA in PBS was injected into each of the C57BL/6
and IRF-4 -/littermates, followed by an injection of 100 l of IFA on the next day. PBS alone was used as a negative control for all experiments. The animals were sacrificed on day 6. Lymphocytes were collected from the spleens. Total CD4 + T-cells were purified using magnetic particles conjugated with anti-CD4 Ab (Imag Cell Separation System, BD Biosciences), as specified by the manufacturer. This protocol provided cells with >99% purity, as assessed by flow cytometry. Freshly isolated CD4 + T-cells were collected by centrifugation and cultured at a density of 1×10 6 cells/ml in six-well plates precoated with various concentrations of anti-TCR mAb (H57-597). Cells were harvested at 16 h for cytokine assays, using sandwich ELISA. For the mRNA preparation, the isolated CD4 + T-cells (2×10 5 cells/well) were stimulated in the 96-well paltes precoated with the indicated concentrations of anti-CD3 (Pharmingen) and anti-CD28 (Southern Biotech) antibodies for 4h. 10 
Results
Identification of the proteins associated with IRF-4 by the TAP method, followed by mass spectrometry
To identify the proteins that associate with IRF-4 in T-cells, we purified the IRF-4-binding complex by the TAP method, as described previously (16) , and in Supplemental Figs. 1S-3S. We excised 30 well-separated bands that were specifically bound to IRF-4 from the gel, digested them with trypsin, and identified them by tandem mass spectrometry. However, only fourteen bands, in addition to IRF-4, were identified with significant scores (p < 0.05) in the Swiss-Prot database, using the MASCOT search engine (Supplemental Table S1 ). One of the peptide sequences acquired from the approximately 75-80 kDa protein band was matched to the human c-Rel proto-oncogene protein.
Specific binding between IRF-4 and c-Rel
We further analyzed the binding of c-Rel to IRF-4, because the enhanced expression of both c-Rel and IRF-4 is associated with the prognosis in ATLL patients (15, 16 ). An IRF-4 was specifically co-precipitated with the FLAG-tagged c-Rel, and the binding was enhanced in the presence of P/I (Fig. 1C ).
Next, we examined the region of c-Rel that is responsible for its interaction with IRF-4, using HA-tagged deletion mutants of c-Rel ( Fig. 2A,B) . 
IRF-4 and c-Rel cooperatively activate the IL-4 promoter
To explore the effects of c-Rel on the IRF-4 functions in vivo, we first examined the effects of c-Rel on the IRF-4-dependent IL-4 stimulation in HUT102 cells, using a luciferase reporter assay with an IL-4 promoter, because IRF-4 reportedly stimulated IL-4 expression via a physical interaction with NFATc2 and/or NFATc1 (9, 14) . As shown in Fig Ionomycin, and plate-bound 0.5g/ml anti-CD3, and 4g/ml anti-CD28 for 4~8 hours to activate T cells otherwise indicated. The treatments with the same amounts of P/I were also employed to stimulate effectively CD4 + T cells, and HUT102 cells.
IRF-4 and c-Rel activate the IL-2 promoter to produce IL-2
IRF-4 is reported to stimulate IL-2 production as well as IL-4 (14) . To examine the effects of IRF-4 and c-Rel on the IL2-promoter, we introduced the plasmids encoding IRF-4
and c-Rel into HUT102 cells. We estimated the amount of IL-2 cDNA by applying different numbers of PCR cycles, after converting the mRNA to cDNA by reverse transcriptase, and evaluating the amount of -actin cDNA as the total amount of mRNA.
As shown in Fig. 4A , substantial amounts of IL-2 cDNA were detected in the presence of P/I, as compared to those in the absence of P/I, and the amount of IL-2 cDNA was increased by exogenously expressing c-Rel or IRF-4. To assess the data quantitatively, we employed the real-time PCR using IL-2 specific primers, and measured the mRNA expression of IL-2 relative to -Actin (Fig.4B ). In the presence of P/I, the exogenous IRF-4 and c-Rel appeared to increase the expression of IL-2 mRNA, but the enhancing effects were not significant (p=0.116 and 0.134). We think that the cooperation of IRF-4 with c-Rel was not observed, because HUT102 cells express a large amount of IRF-4, and thus the increases of IL-2 cDNA by IRF-4 or c-Rel were relatively small. Indeed, in EL-4 cells, a cooperative effect of IRF-4 with c-Rel on IL-2 production was observed, by measuring the amounts of IL-2 produced from the cells transfected with the plasmids encoding IRF-4 and c-Rel, using an ELISA (Fig. 4C ). However, any detectable amounts of IL-4 were not produced by any combinations of the reagents (Fig.4D ). The roles of IRF-4 and c-Rel in IL-2 and IL-4 promoter activations are different in cell types and specific conditions. For example, c-Rel is indispensable for the optimal IL-2 production in naïve T-cells, but is not required in for the IL-2 production in blast T-cells (19) . IRF-4 is also reported to differentially regulates the production of Th2 cytokines including IL-4 in naïve vs. effector/memory CD4 + T cells (20) .
The specific roles of the c-Rel and IRF-4 interaction in the activation of the IL-2 and IL-4
promoters should be elucidated in specific cells and proper conditions.
Optimal IL-2 amd IL-4 productions require IRF-4 in vivo
Next, we examined the effects of IRF-4 on IL-2 and IL-4 productions in vivo using (19) . Therefore, we measured the IL-2 and IL-4 expressions in splenic CD4 + T-cells from normal and IRF-4 -/mice, by anti-CD3 stimulation with and without TNF- pretreatment.
The amount of IL-2 mRNA in IRF-4-deficient cells (IRF-4 -/-) was significantly lower than that in normal cells, as evaluated by quantitative real time PCR (WT) (Fig. 5A ). These results indicated that not only c-Rel but also IRF-4 is required for the optimal production of IL-2 in TNF--primed T-cells. On the other hand, we could not detect any IL-4 mRNA by anti-CD3 stimulation even in TNF--primed T-cells from WT or IRF-4 -/mice ( Fig. 5B ).
We further examined the effects of complete Freund's adjuvant (CFA)-mediated priming on the IL-2 production in splenic CD4 + T-cells. Naive T-cells from CFA-primed normal (WT), but not IRF-4 -/-, mice produced high levels of IL-2 in response to anti-CD3 stimulation (termed superinduction), dependent on the amount of TCR antibody (Fig. 5C ).
The priming effect of CFA was completely absent in the IRF-4-deficient T-cells. To elucidate the mechanism of high IL-2 production, we examined the priming effects on the IL-2 promoter activity by measuring IL-2 mRNA with real time PCR (Fig.6A) . The IL-2 mRNA amounts enhanced by TCR stimulation with the anti-CD3 and anti-CD28 antibodies were CFA-dependent in the WT mice-derived CD4 + T-cells. The CFA-dependent superinduction was disappeared in IRF-4 -/mice, as reported in c-Rel -/mice. These indicated that IRF-4 as well as c-Rel is indispensable to fully activate IL-2 promoter in vivo.
As for IL-4 regulation, the IL-4 production stimulated with TCR antibody was also dependent on the CFA priming in WT, although the amounts of IL-4 were much smaller than those of IL-2 ( Figs. 5C and 5D ). The TCR activation-dependent IL-4 mRNA amounts were significantly lower in the IRF-4 -/mice compared to WT mice, but the CFA-dependence was not observed (Fig. 6B ) These suggested that the regulations of IRF-4 may be different in the IL-2 and IL-4 promoters. The discrepancy between the protein and mRNA levels of IL-4 may be caused by the effects of IRF-4 on the stability of IL-4 protein, in addition to the effects on the promoter. Another possibility of the discrepancy between the IL-4 protein and mRNA levels was due to the different sensitivities of the detection systems employed here. The differences in mRNA expression measured at 4h after TCR stimulation may be not enough to assess the IL-4 promoter activities, considering that the IL-4 protein levels measured by ELISA reflect the continuous effects during 16 hours, and that the differences of IL-4 amounts were much smaller than those of IL-2.
Discussion
In the present study, we isolated a protein complex associated with IRF-4 in HTLV-1-infected T-cells using the TAP method, and showed that an NF-B family member, In contrast, our data suggested that IRF-4 worked mainly on the IL-2 promoter activation, and the activation was may be in cooperation with c-Rel. The IL-2 promoter activation by IRF-4 required P/I treatment or TCR stimulation with cytokine priming (Fig.   4~6 ). These results suggested that qualitative changes of IRF-4 and/or c-Rel, their possible interacting molecules, and the chromatin structure in the IL-2 proximal promoter region by such as phosphorylation, acetylation, and demethylation may be necessary for optimal IL-2 promoter activation (29) . The absence of ISRE site in the IL-2 proximal promoter region, compared to the IL-4 promoter, may be involved in the difference. In addition, c-Rel was recently reported to be required for the development of thymic Foxp3 + CD4 regulatory T-cells (Treg) (30) , and Foxp3-dependent IRF-4 induction in Treg is thought to be important for the Treg function to control the Th2 response (31) . Therefore, regulating the interaction between IRF-4 and c-Rel by manipulating the molecules may help to differentiate from pluripotent T-cells into specific lineage to treat various diseases (32) .
In conclusion, the elucidation of the physical and functional cooperation between IRF-4 and c-Rel to activate of the IL-4 and IL-2 genes in T-cells, is important for future gene therapy for ATLL by abolishing their growth effects, and to present promising targets for adoptive immunotherapy by regulating specific T-cell development. 25 30 35 PCR cycle number 25 30 35 PCR cycle number 25 30 35 PCR cycle number 25 3
Figure legends
Results
Identification of the proteins associated with IRF-4 by the TAP method, and subsequent mass spectrometry
To identify the proteins that associate with IRF-4 in T-cells, we purified IRF-4-binding complex by the TAP method, as described previously. Supplemental Fig.1S illustrates the purification procedures of specific binding proteins to the target TAP-tagged protein (TAP-tagged IRF-4) using two different affinity columns. The final eluates containing the IRF-4-binding protein complex (Supplemental Fig.2S-B , EGTA) were separated on a 4-20% SDS-PAGE gradient gel and visualized with a Negative Gel Stain MS Kit (Supplemental Fig.2S, IRF4-TAP) . Compared to the control experiment (WT) using the same amount of HUT102 cells without transfection of the target TAP-tagged IRF4 expression plasmid, as many as 50 bands were stronger than the control. We excised wellseparated 30 bands from the gel, digested by trypsin and identified by tandem mass spectrometry. However, only the fourteen bands in addition to IRF4 were identified with significant scores (p < 0.05) in the Swiss-Prot database, using the MASCOT search engine (Supplemental Table S1 ). One of the peptide sequences acquired from the approximately 75-80 kDa protein band was matched to the human c-Rel proto-oncogene protein with 160
Mowse score and covering 13% of the c-Rel entire 560 amino acids sequence in independent 7 peptides (p=0.001).
Optimization of T-cell activation with PMA, and Ionomycin, and T-cell receptor (TCR)
antibodies.
We optimized the T-cell activations using EL-4 mouse T-cells, and used 250ng/ml 4 PMA, and 1M Ionomycin, and plate-bound 0.5g/ml anti-CD3, and 4g/ml anti-CD28 for 4~8 hours to activate T cells otherwise indicated. The treatments with the same amounts of P/I, were also employed to stimulate effectively CD4 + T cells, and HUT102 cells. 
